News
IKNA
1.320
0.00%
0.000
Weekly Report: what happened at IKNA last week (0422-0426)?
Weekly Report · 04/29 11:34
Weekly Report: what happened at IKNA last week (0415-0419)?
Weekly Report · 04/22 11:21
Weekly Report: what happened at IKNA last week (0408-0412)?
Weekly Report · 04/15 11:13
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum. The Company will also be holding one-on-one investor meetings at the event. Ikena oncology, Inc. Is forging new territory in patient-directed cancer treatment.
Barchart · 04/10 07:00
Weekly Report: what happened at IKNA last week (0401-0405)?
Weekly Report · 04/08 11:18
Weekly Report: what happened at IKNA last week (0325-0329)?
Weekly Report · 04/01 11:16
Weekly Report: what happened at IKNA last week (0318-0322)?
Weekly Report · 03/25 11:19
The Analyst Landscape: 4 Takes On Ikena Oncology
4 analysts have expressed a variety of opinions on Ikena Oncology (NASDAQ:IKNA) over the past quarter. The company is a targeted oncology company developing precision therapies for patients in need. The average price target of $10.25 is 6.82% lower than the 12-month average for the company. The company's revenue growth lags behind its peers.
Benzinga · 03/19 12:01
HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $11 Price Target
Benzinga · 03/19 11:05
Ikena Oncology’s IK-595: A Promising Contender in the MAPK-Driven Tumor Space
In a report released today, Andres Y. Maldonado maintained a Buy rating on Ikena Oncology (IKNA) with a price target of $11.00. H.C. Wainwright says the company has potential to overcome MAPK-driven tumors. The company is focused on developing novel cancer therapies.
TipRanks · 03/19 10:27
Weekly Report: what happened at IKNA last week (0311-0315)?
Weekly Report · 03/18 11:17
Ikena Oncology’s Promising Drug Pipeline Merits a Buy Rating
TipRanks · 03/12 22:05
Ikena Oncology: Q4 Earnings Insights
Ikena Oncology reports its Q4 earnings results on March 12. The company beat estimates by 5.0%. Revenue was down $4.79 million from the same period last year. Last quarter the company beat on EPS by $0.03. Ikena oncology is expected to announce its earnings Tuesday morning.
Benzinga · 03/12 21:05
Ikena Oncology Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 03/12 14:59
Ikena Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/12 14:59
Ikena Oncology’s IK-930: A Promising Contender in Targeted Oncology Treatments
TipRanks · 03/12 14:55
HC Wainwright & Co. Maintains Buy on Ikena Oncology, Maintains $11 Price Target
Benzinga · 03/12 14:49
Ikena Oncology Inc reports results for the quarter ended in December - Earnings Summary
Ikena Oncology Inc reports results for the quarter ended in December. Revenue fell 87.9% to $659.00 thousand from a year ago. The company reported a quarterly adjusted loss of 47 cents per share. The mean expectation of five analysts was for a loss of 43 cents.
Reuters · 03/12 13:31
Ikena Oncology Q4 EPS $(0.41) Beats $(0.43) Estimate, Sales $658.00K Miss $3.14M Estimate
Ikena Oncology reported quarterly losses of $0.41 per share. The company reported quarterly sales of $658.00 thousand. Ikena oncology beat the analyst consensus estimate of $3.14 million for the same period last year.  
Benzinga · 03/12 12:06
*Ikena Oncology 4Q Loss $19.5M >IKNA
Dow Jones · 03/12 12:01
More
Webull provides a variety of real-time IKNA stock news. You can receive the latest news about Ikena Oncology through multiple platforms. This information may help you make smarter investment decisions.
About IKNA
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.